Binding of thalidomide to CRBN was shown to inhibit CUL4A-dependent E3 ligase activity, and thalidomide promoted CRBN-dependent degradation of specific transcription factors that play a critical role in B cell malignancies including myeloma [41,42]. Here, CRBN is linked to plasma cell myeloma.